Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Clinical neurodiagnostics

Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment.

Giulia Giacomucci; Salvatore Mazzeo; Silvia Bagnoli; Assunta Ingannato; Deborah Leccese; Valentina Berti; Sonia Padiglioni; Giulia Galdo; Camilla Ferrari; Sandro Sorbi; Valentina Bessi; Benedetta Nacmias

Originally published in Journal of neurology · 2022-03-14

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Introduction Neurofilament light chain (NfL) is becoming increasingly notable in neurological diseases including AD, and it has been suggested as a new peripherical biomarker of neurodegeneration. We aimed to compare plasma NfL levels among Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), and AD patients and to evaluate relationships between NfL and CSF biomarkers and neuropsychological scores. Materials and methods We enrolled 110 patients (34 SCD, 53 MCI, and 23 AD), who underwent clinical and neuropsychological evaluation, APOE genotyping, and plasma NfL analysis. Ninety-one patients underwent at least one amyloid burden biomarker (CSF and/or amyloid PET); 86 patients also underwent CSF phosphorylated-tau (p-tau) and total-tau (t-tau) measurement. Patients were classified as A + if they presented at least one positive amyloid biomarker or A- if not. Results NfL levels were significantly increased in AD and MCI compared to SCD patients. These differences depend on A status, e.g., SCD A + had lower NfLs than MCI A + but comparable with MCI A-. Similarly, MCI A + had higher NfL levels than MCI A-, but comparable with AD.

Discussion

Our study aimed to explore differences in plasma NfL levels in SCD, MCI, and AD patients, focusing on both prodromal and preclinical stages of AD. As the main result, we found that plasma NfL levels were different among patients depending on the cognitive status (SCD, MCI, or AD) and on the underlying pathology (presence or absence of amyloid). In more details, MCI and AD patients had higher plasma NfL levels as compared to SCD. Furthermore, plasma NfL concentrations in MCI A + were higher than MCI A− and SCD A + , but consistent with AD patients.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?